In a recent study, researchers sought to determine the potential for the overdiagnosis of breast cancer after screening for women 70 years of age and older.
Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
In a post hoc analysis of two phase 3 trials, researchers set out to determine the impact of sex on tofacitinib in terms of efficacy, safety, and time to discontinuation.